Yantai Shenghua Biotechnology Co., Ltd. (hereinafter referred to as "Shenghua Biotech") was established in November 2023 and is located in the Laishan Industrial Park in Yantai, Shandong. It serves as the core production base of Yantai Huaxin Synthetic Biotechnology Co., Ltd., specializing in the industrialization of biosynthetic technology. It has established an integrated industrial closed loop encompassing "research and development - pilot testing - mass production", providing full-chain production support for front-end research and development.

The company focuses on the production of intermediates and core excipients in the fields of biomedicine, food, and health products, with a primary emphasis on the large-scale production and technological transformation of peptide drugs, key materials for chemical drugs, solid-phase synthesis carriers, and microsphere products. Equipped with a professional R&D team, R&D center, small-scale and pilot laboratories, as well as standardized production bases and dedicated workshops, the company has established a comprehensive equipment system for microsphere preparation, achieving seamless integration from technology to industrialization.

Significant core advantages: We master 8-10 production technologies for peptide synthetic resin, replacing internationally banned technologies with non-toxic processes, and our products cater to diverse needs. As one of the few domestic enterprises possessing membrane emulsification microsphere preparation technology, we can provide laboratory-grade to industrial equipment, customize high value-added products, and deliver integrated process solutions.

Relying on Huaxin Synthetic Biological Resources, the company has deep cooperation with research institutions such as Hong Kong Senco Science and GBIO Science in the United States, serving customers in mainland China, Hong Kong, and the United States. In 2025, it was approved as a national technology-based SME and is currently applying for national high-tech enterprise status. In the future, it will continue to strengthen technology transformation and mass production capabilities, providing high-quality products and services to research institutions and corporate customers, and promoting the widespread application of biosynthetic technology